PSY9 A Budget Impact Model of Rituximab Introduction in Wegener Granulomatosis Therapies
نویسندگان
چکیده
منابع مشابه
Endonasal dacryocystorhinostomy in wegener granulomatosis.
Wegener granulomatosis (WG) is a life-threatening autoimmune disease of unknown etiology first described in 1936. The classic clinical triad consists of necrotizing granulomatous inflammation of the respiratory tract, necrotizing glomerulonephritis, and systemic vasculitis. Prior to the introduction of modern immunosuppressants, WG was usually fatal due to renal complications. Involvement of th...
متن کاملGranulomatous Choroiditis in Wegener Granulomatosis
Author Affiliations: Department of Ophthalmology, Emory Eye Center, Atlanta, Georgia (Drs Payne, Wells, and Grossniklaus); and Department of Ophthalmology, Cole Eye Institute, Cleveland, Ohio (Dr Srivastava). Correspondence: Dr Grossniklaus, Department of Ophthalmology, Emory Eye Center, 1365 B Clifton Rd, Room BT428, Atlanta, GA 30322 ([email protected]). Author Contributions: All of the autho...
متن کاملWegener granulomatosis--rare case presentation.
Wegener granulomatosis is often misdiagnosed as pneumonia and most common cause for bilateral lung infiltrates' are bacterial, viral, pneumocystis jiroveci infection. We describe a 35 year old female with 15 days history of nasal obstruction, breathlessness and fever. Investigations in this patient revealed chronic necrotizing vasculitic and granulomatous lesion in nasal biopsy, vasculitic pauc...
متن کاملWegener granulomatosis (granulomatosis with polyangiitis): evolving concepts in treatment.
Wegener granulomatosis (WG), the most common of the pulmonary granulomatous vasculitides, typically involves the upper respiratory tract, lower respiratory tract (bronchi and lung), and kidney, with varying degrees of disseminated vasculitis. THE TERM GRANULOMATOSIS WITH POLYANGIITIS (WEGENER) WAS RECENTLY PROPOSED TO REPLACE THE OLDER TERM, WG. THE TERM GRANULOMATOSIS WITH POLYANGIITIS CAN BE ...
متن کاملBudget impact model of rituximab after failure of one or more TNFalpha inhibitor therapies in the treatment of rheumatoid arthritis.
OBJECTIVES To estimate the budget impact implied by the introduction of rituximab after failure of one or more anti-TNFalpha therapies in the perspective of the French health care system. METHODS A Markov model reproduced the course, over 4years, of patients treated either by infliximab, etanercept, adalimumab or RTX, after failure of one or more anti-TNFalpha therapies, in a multicentric stu...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Value in Health
سال: 2011
ISSN: 1098-3015
DOI: 10.1016/j.jval.2011.08.982